TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 0
Operating Income -59.1M
Net Income -57.5M
EPS (Diluted) $-1.09

Balance Sheet Metrics

Total Assets 297.9M
Total Liabilities 189.1M
Shareholders Equity 108.8M
Debt to Equity 1.74

Cash Flow Metrics

Operating Cash Flow -34.9M
Free Cash Flow -29.3M

Revenue & Profitability Trend

Kodiak Sciences Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i00000
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i126.1M206.3M267.6M217.3M107.4M
Selling, General & Administrative i60.8M71.0M73.8M49.7M28.6M
Other Operating Expenses i-----
Total Operating Expenses i186.8M277.3M341.4M267.1M136.0M
Operating Income i-186.8M-277.3M-341.4M-267.1M-136.0M
Operating Margin % i0.0%0.0%0.0%0.0%0.0%
Non-Operating Items
Interest Income i11.1M16.7M7.1M298.0K3.0M
Interest Expense i013.0K18.0K47.0K25.0K
Other Non-Operating Income-506.0K110.0K503.0K-190.0K-30.0K
Pre-tax Income i-176.2M-260.5M-333.8M-267.0M-133.1M
Income Tax i-----
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-176.2M-260.5M-333.8M-267.0M-133.1M
Net Margin % i0.0%0.0%0.0%0.0%0.0%
Key Metrics
EBITDA i-149.5M-234.5M-322.8M-258.2M-128.9M
EPS (Basic) i-$-4.97$-6.39$-5.16$-2.91
EPS (Diluted) i-$-4.97$-6.39$-5.16$-2.91
Basic Shares Outstanding i-52414256522496205178891845741845
Diluted Shares Outstanding i-52414256522496205178891845741845

Income Statement Trend

Kodiak Sciences Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i168.1M285.5M190.4M731.5M944.4M
Short-term Investments i-0288.5M024.6M
Accounts Receivable i-----
Inventory i-----
Other Current Assets3.9M3.8M7.1M3.3M3.0M
Total Current Assets i171.9M289.3M486.0M734.8M972.0M
Non-Current Assets
Property, Plant & Equipment i46.5M54.5M59.4M66.7M77.0M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets14.9M15.0M64.9M61.3M16.5M
Total Non-Current Assets i163.6M190.1M180.6M169.4M95.3M
Total Assets i335.6M479.4M666.6M904.2M1.1B
Liabilities
Current Liabilities
Accounts Payable i3.9M13.6M9.1M12.4M8.6M
Short-term Debt i10.6M9.8M9.9M3.9M2.4M
Current Portion of Long-term Debt-----
Other Current Liabilities---1.0K--
Total Current Liabilities i25.6M41.7M52.5M64.7M31.4M
Non-Current Liabilities
Long-term Debt i59.7M71.9M77.8M76.1M75.0M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities100.0M100.0M100.2M211.0K256.0K
Total Non-Current Liabilities i159.7M171.9M178.0M176.2M175.2M
Total Liabilities i185.3M213.6M230.5M240.9M206.6M
Equity
Common Stock i5.0K5.0K5.0K5.0K5.0K
Retained Earnings i-1.3B-1.2B-892.0M-558.2M-291.2M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i150.3M265.8M436.2M663.3M860.8M
Key Metrics
Total Debt i70.3M81.6M87.7M80.0M77.4M
Working Capital i146.4M247.6M433.5M670.1M940.6M

Balance Sheet Composition

Kodiak Sciences Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-176.2M-260.5M-333.8M-267.0M-133.1M
Depreciation & Amortization i26.7M25.9M11.0M8.7M4.2M
Stock-Based Compensation i60.2M88.6M106.0M61.4M30.7M
Working Capital Changes i-21.0M-2.9M17.0M1.2M1.4M
Operating Cash Flow i-109.9M-148.9M-200.4M-195.7M-96.7M
Investing Activities
Capital Expenditures i-400.0K-41.4M-47.4M-63.3M-7.0M
Acquisitions i-----
Investment Purchases i-355.0K-49.3M-427.8M0-86.3M
Investment Sales i0340.0M138.6M24.5M198.1M
Investing Cash Flow i-755.0K249.2M-336.5M-38.8M104.8M
Financing Activities
Share Repurchases i--00-487.0K
Dividends Paid i-----
Debt Issuance i----0
Debt Repayment i--00-5.0K
Financing Cash Flow i--211.0K-49.0K-45.0K711.1M
Free Cash Flow i-117.7M-195.6M-253.8M-245.6M-90.4M
Net Change in Cash i-110.6M100.1M-537.0M-234.5M719.2M

Cash Flow Trend

Kodiak Sciences Key Financial Ratios

Valuation Ratios

Forward P/E -2.12
Price to Book 3.90
PEG Ratio -2.12

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -108.92%
Return on Assets -34.10%

Financial Health

Current Ratio 4.62
Debt to Equity 62.14
Beta 2.42

Per Share Data

EPS (TTM) $-3.62
Book Value per Share $2.07

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
kod425.3M-3.90-108.92%0.00%62.14
Vertex 121.3B32.827.0522.77%31.86%8.89
Regeneron 60.4B14.371.9815.34%31.37%9.04
Harmony Biosciences 2.0B13.132.7424.71%20.50%24.63
Ocular Therapeutix 2.0B-7.40-57.19%91.17%28.66
Beam Therapeutics 1.9B-3.851.59-51.36%0.00%14.08

Financial data is updated regularly. All figures are in the company's reporting currency.